Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

28.75 -0.25 (-0.86%)

Streaming Delayed Price Updated: 12:42 PM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

December 04, 2024

Via Benzinga

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

December 04, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

December 02, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics ↗

June 28, 2024

Via Benzinga

Analyst Expectations For Stoke Therapeutics's Future ↗

May 06, 2024

Via Benzinga

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

November 05, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

September 10, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Assessing Stoke Therapeutics: Insights From 6 Financial Analysts ↗

April 04, 2024

Via Benzinga

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

September 04, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

September 03, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

September 03, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

August 16, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

August 07, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

July 16, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday ↗

June 24, 2024

Via Benzinga

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

June 18, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

June 03, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 17, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 06, 2024

STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 06, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

April 29, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

April 17, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 05, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 04, 2024

Via Benzinga

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 04, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

March 27, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 27, 2024

Via Benzinga

What's Going On With Stoke Therapeutics Stock Tuesday? ↗

March 26, 2024

After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a...

Via Benzinga

Stoke Therapeutics Announces Proposed Public Offering

March 26, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates ↗

March 26, 2024

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday. The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.